Risk Of Developing Liver Cancer After HCV Treatment

Tuesday, January 29, 2013

Janssen and Idenix - The Newest Hep-C Partnership

Investment Commentary

Source - The Motley Fool

A collaboration between Janssen and Idenix is the highlight of this video. The collaboration will evaluate combinations using the following investigational HCV drugs; simeprevir formerly referred to as TMC435 a protease inhibitor developed by Janssen R&D Ireland and Medivir, TMC647055 a polymerase inhibitor by Janssen and Idenix's IDX719 a NS5A inhibitor. The clinical hold on IDX184 in relation to the outcome of Bristol-Myers tragic trial with drug BMS-986094 is also included in the video.




Related-

New Interferon-free Development Program
Alan Franciscus
Editor-in-Chief, HCV Advocate
January 28 2013 - Medivir announced a collaboration between Medivir/Janssen and Idenix for the clinical development of multiple HCV inhibitors with and without ribavirin—all the studies will be interferon-free.
Continue reading....

Press Release
Medivir: Phase II all-oral combination studies of Simeprevir, TMC647055 and IDX719 for the treatment of Hepatitis C to be initiated shortly


No comments:

Post a Comment